Pharmatopinol was listed on the Hong Kong Stock Exchange in November 2020. The significant 373.1% year-over-year increase in revenue for the year ended December 31, 2022 was driven by Benoda ® (Rechiolencel Injection), the company's cellular immunotherapy product for the treatment of relapsed or refractory large B-cell lymphoma in adult patients following second-line or above systemic therapy. The product was successfully commercialized on September 1, 2021 after being approved by the China National Medical Products Administration.

Benoda ® (Rechiolencel injection) is a lentiviral vector targeting CD19 CAR T cell therapy product independently developed by Pharming Junol. It is also the only CAR T cell therapy product in China that has won the "Major New Drug development" special award, the priority review qualification of new drug marketing application and breakthrough therapy drug recognition.

At the symposium, Chairman Shi Yuanyuan made a detailed introduction on the development history, core technical team, R&D and production pipeline and core advantages of Shenzhen Cell Valley, and chief scientist Professor Wang Jianxun made an introduction on the international use trend of retroviral vectors and core technical issues related to vector optimization. The two sides carried out heated discussions on the international and domestic markets of retroviral vectors, the development of new pipeline of cell products, and the application of IIT clinical trials. At present, the sales of listed cell products are closely related to their selling price, so it is particularly important to reduce their industrialization costs, whether in industrialization cost or safety, retroviral vectors have unique advantages, Shenzhen Cell Valley as the only service platform that can industrialize the production of retroviral vectors, with unique advantages in the industrial production of retroviral vectors. Gu Haihua said that the subsequent development of the new pipeline will try to reverse the virus vector new track, its advantages are not only reflected in the expansion of cell product production capacity, but also reflected in the significant reduction of industrialization costs.

The two sides said that they will consider cooperation in the development of new pipelines, IIT clinical research and other aspects, accelerate the process of innovation and development, and strive to bring more innovations and breakthroughs in the field of cell and gene therapy!